Compare · LNSR vs SYK
LNSR vs SYK
Side-by-side comparison of LENSAR Inc. (LNSR) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNSR and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $115.59B, about 1705.3x LNSR ($67.8M).
- Over the past year, LNSR is down 57.4% and SYK is down 18.9% - SYK leads by 38.5 points.
- LNSR has been more active in the news (13 items in the past 4 weeks vs 8 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 3 for LNSR).
- Company
- LENSAR Inc.
- Stryker Corporation
- Price
- $5.57+0.45%
- $310.12+2.82%
- Market cap
- $67.8M
- $115.59B
- 1M return
- +5.69%
- +8.61%
- 1Y return
- -57.35%
- -18.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 13
- 8
- Recent ratings
- 3
- 25
LENSAR Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest LNSR
- Director Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Director Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Principal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)
- Chief Operating Officer Connaughton Alan B. was granted 34,843 shares, increasing direct ownership by 10% to 389,173 units (SEC Form 4)
- Chief Executive Officer Curtis Nicholas T was granted 130,662 shares, increasing direct ownership by 13% to 1,122,758 units (SEC Form 4)
- Director Weisner Aimee S was granted 17,421 shares, increasing direct ownership by 19% to 110,368 units (SEC Form 4)
- Director O'Farrell Elizabeth G. was granted 17,421 shares, increasing direct ownership by 35% to 67,368 units (SEC Form 4)
- Director Winer Gary M was granted 17,421 shares, increasing direct ownership by 20% to 105,635 units (SEC Form 4)
- Director Lindstrom Richard L Md was granted 17,421 shares, increasing direct ownership by 7% to 263,831 units (SEC Form 4)
- Director Link William J Phd was granted 17,421 shares, increasing direct ownership by 3% to 568,062 units (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation